Board of Directors

Martin Nicklasson

Chair of the Board
Chair of the Remuneration Committee; member of the Audit and Nomination Committees.

Elected to the Board in 2015 and regarded as an independent board member.

Special competencies
Extensive general management and research and development experience from AstraZeneca Plc and Swedish Orphan Biovitrum AB.

Current positions
Board member of Basilea Pharmaceutica Ltd. and chairman of Nykode Therapeutics AS.

Kirsten A. Drejer

Vice Chair of the Board
Chair of the Scientific Committee; Chair of the Nomination Committee.

Elected to the Board in 2018 and regarded as an independent board member.

Special competencies
More than 30 years of international experience in the pharmaceutical and biotech industry. Before co-founding Symphogen A/S in 2000, held several scientific and managerial positions at Novo Nordisk A/S.

Current positions
Chair of the Board of Bioneer and ResoTher Pharma. Board member of Curasight A/S and Malin Corporation.

Jeffrey Berkowitz

Board member
Member of the Audit Committee.

Elected to the Board in 2019 and regarded as an independent board member.

Special competencies
Global executive with extensive branded and generic pharmaceutical, retail pharmacy, wholesale drug distribution, specialty, payor and healthcare services leadership experience in P&L accountable roles.

Current positions
CEO and Director of Real Endpoints. Board member of H. Lundbeck A/S, Esperion Therapeutics, Inc. and Uniphar PLC.

Bernadette Connaughton

Board member
Member of the Audit Committee.

Elected to the Board in 2019 and regarded as an independent board member.

Special competencies
More than 30 years of global strategic, commercial and leadership expertise, and a broad perspective on the strategy, capabilities and governance required for successful execution in U.S. and international markets.

Current Positions
Board member of Halozyme Therapeutics Inc. and Editas Medicine.

Leonard Kruimer

Board member
Chair of the Audit Committee; Member of the Remuneration and Nomination Committees.

Elected to the Board in 2019 and regarded as an independent board member.

Special competencies
More than 30 years of experience in corporate finance, planning and strategy, including 15 years in senior executive positions in private and publicly listed biotechnology companies.

Current positions
Chair of the Board of BioInvent International AB, Board member and Chair of Audit Committee of Pharming Group NV., and Basilea Pharmaceutica Ltd. Director AI Global Investments (Netherlands).

Enrique Conterno Martinelli

Board member
Member of the Remuneration and Scientific Committees.

Elected to the Board in 2024 (Board Observer from 2023) and regarded as an independent board member.

Served at Eli Lilly and Company as SVP and a member of the executive committee; president of Lilly USA from January 2017 and president of Lilly Diabetes from 2009 until retirement from Eli Lilly and Company in 2019. 

Current positions
Member of the board of Glooko, Inc.; member of the board of governors of the American Red Cross.

Elaine Sullivan

Board member
Member of the Scientific Committee.

Elected to the Board in 2024 (Board Observer from 2023) and regarded as an independent board member.

Served at AstraZeneca and Eli Lilly and Company as a member of the senior global R&D management teams.  

Current positions

Member of the board of Nykode Therapeutics ASA, IP Group plc, and hVIVO Ltd; member of the supervisory board of Evotec AG.

Frederik Barfoed Beck

Employee-elected board member
Elected to the Board in 2020.

Current positions
Associate Director, Contracts and Sourcing.

Anneline Nansen

Employee-elected board member
Elected to the Board in 2024 (instated as first alternate to the Board in 2021).

Current positions
Principal Scientist.

Adam Krisko Nygaard

Employee-elected board member
Elected to the Board in 2024.

Current positions
Senior Statistical Programmer.

Ludovic Tranholm Otterbein

Employee-elected board member
Elected to the Board in 2024.

Current positions
Vice President, Head of IT.